Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance


Affiliations: 1Institute for Global Health, University College London, London, UK. 2Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. 3Respiratory Medicine, Homerton University Hospital, London, UK. 4Tuberculosis Unit, National Infection Service, Public Health England, London, UK. 5Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. 6Respiratory Medicine, Royal Free Hospital, London, UK. 7UCL Respiratory, Division of Medicine, University College London. 8Respiratory Medicine, North Middlesex University Hospital, London, UK. 9Infectious Diseases, London North West University Healthcare NHS Trust, London, UK. 10National Mycobacterial Reference Service South, Public Health England, London, UK. 11Tuberculosis Service, University College London Hospitals/Whittington Health, London, UK. 12Respiratory Medicine, Barnet General Hospital, Royal Free London NHS Foundation Trust, London, UK. 13Statistics, Modelling and Economics Department, Public Health England, London, UK. 14TB Service, Imperial College Healthcare, London, UK. 15Respiratory Medicine, Chelsea and Westminster Hospital, London, UK. 16Centre for Clinical Microbiology, University College London, London, UK. 17Respiratory Medicine, Guy’s and St Thomas’ Hospital, London, UK. 18Respiratory Services, Queen Elizabeth Hospital, London, UK. 19Dept of Medicine and Dept of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. 20Additional London INH-R TB study group members are listed in the acknowledgements section. 21These authors contributed equally to this manuscript and are presented alphabetically. 22These authors contributed equally to this manuscript and are presented alphabetically.

Correspondence: Helen R. Stagg, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH8 9DX, UK. E-mail: helen.stagg@ed.ac.uk

@ERSpublications
WHO has assessed regimen recommendations for isoniazid-resistant TB to be of very low certainty. The addition of fluoroquinolones to a 12-month (isoniazid, rifamycin, ethambutol, short-duration pyrazinamide) regimen may be unnecessary in certain settings. http://bit.ly/2XoTgNL


This single-page version can be shared freely online.
fluoroquinolones (Fq) on treatment effectiveness, accounting for Hr mutations and degree of phenotypic resistance.

**Methods:** This was a retrospective cohort study of 626 Hr tuberculosis patients notified in London, 2009–2013. Regimens were described and logistic regression undertaken of the association between regimen and negative regimen-specific outcomes (broadly, death due to tuberculosis, treatment failure or disease recurrence).

**Results:** Of 594 individuals with regimen information, 330 (55.6%) were treated with (H)RfZE (Rf=rifamycins) and 211 (35.5%) with (H)RfZE-Fq. The median overall treatment period was 11.9 months and median Z duration 2.1 months. In a univariable logistic regression model comparing (H)RfZE with and without Fqs, there was no difference in the odds of a negative regimen-specific outcome (baseline (H) RfZE, cluster-specific odds ratio 1.05 (95% CI 0.60–1.82), p=0.87; cluster NHS trust). Results varied minimally in a multivariable model. This odds ratio dropped (0.57, 95% CI 0.14–2.28) when Hr genotype was included, but this analysis lacked power (p=0.42).

**Conclusions:** In a high-income setting, we found a 12-month (H)RfZE regimen with a short Z duration to be similarly effective for Hr tuberculosis with or without a Fq. This regimen may result in fewer adverse events than the WHO recommendations.